Patent 9549916 was granted and assigned to Novartis on January, 2017 by the United States Patent and Trademark Office.
This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.